Pre-earnings options volume in Cidara Therapeutics is normal with calls leading puts 17:1. Implied volatility suggests the market is anticipating a move near 29.3%, or 0c, after results are released. Median move over the past eight quarters is 2.5%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CDTX:
- Cidara Therapeutics options imply 14.0% move in share price post-earnings
- Cidara Therapeutics Presents Preclinical Data on CD73-Targeting Drug-Fc Conjugate at the 2023 ESMO Targeted Anticancer Therapies Congress
- Cidara Therapeutics Announces Closing of Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares in Public Offering of Common Stock
- Cidara Therapeutics options imply 20.0% move in share price post-earnings
- Cidara Therapeutics Announces Pricing of Public Offerings of Common Stock and Preferred Stock